Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517820 | 1.00 | EGFR (0.32) | EGFRSRCMEN1MAPTHPGD | |
| SCHEMBL23496639 | 0.83 | — | — | |
| SCHEMBL19995552 | 0.83 | — | — | |
| SCHEMBL29813218 | 0.83 | — | — | |
| SCHEMBL2077254 | 0.83 | MPO (0.35) | HPGD | |
| SCHEMBL955712 | 0.83 | HTT (0.33) | — | |
| SCHEMBL20535022 | 0.83 | TAAR1 (0.33) | HPGD | |
| SCHEMBL7103045 | 0.80 | KIF11 (0.38) | MEN1MAPTHPGDKMT2A | |
| SCHEMBL3028315 | 0.78 | TUBB1 (0.38) | MAPT | |
| SCHEMBL11982404 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-3983417-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| CN-119874565-A | Mono cyano diaryl ethylene preparation method of class compound | 常州大学 | 2025-04-25 | — | — | CN | disclosed |
| US-12227521-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-3983417-A1 | CGRP ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-114245797-A | CGRP antagonist compounds | 赫普泰雅治疗有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| WO-2021250279-A1 | ORGANIC LIGHT EMITTING DIODE AND DEVICE COMPRISING THE SAME | NOVALED GMBH (DE) | 2021-12-16 | — | — | WO | disclosed |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2019-11-07 | — | — | US | disclosed |
| EP-3515433-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2019-07-31 | — | — | EP | disclosed |
| CN-109715155-A | blood brain barrier-penetrating agent dopamine- β -hydroxylase inhibitors | 巴尔-波特拉及康邦亚股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| US-6528657-B2 | For use in electroluminescence light emission element and can emit lights of various colors when an energy such as electric energy or electromagnetic energy is applied thereto | TAIHO INDUSTRIES CO., LTD. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20030023099-A1 | Novel fluorescent carbazole derivative | HIROSE ENGINEERING CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| US-4935420-A | MICROBIOCIDES, ANTISEPTICS | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| US-4880806-A | BACTERICIDES | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4874764-A | ANTIMICROBIALS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-10-17 | — | — | US | disclosed |
| US-4855292-A | ANTIMICROBIAL AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | EGFR 2342/4885SRC 4641/4885MEN1 1432/4885 |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | EGFR 2116/4885SRC 4427/4885MEN1 2536/4885 |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | EGFR 2342/4885SRC 4641/4885MEN1 1432/4885 |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | EGFR 2212/4885SRC 4525/4885MEN1 2929/4885 |
| US-12227521-B2 | CGRP antagonist compounds | CALCRL, CALCR, OPRL1 | EGFR 2342/4885SRC 4641/4885MEN1 1432/4885 |
| US-20030023099-A1 | Novel fluorescent carbazole derivative | CBR3, AANAT, SIRT3 | EGFR 3458/4885SRC 2158/4885MEN1 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.